PROGRESS-AD Efficacy and safety of GSK4527226 in participants with early Alzheimer's disease Sponsor GlaxoSmithKline Clinical Trial Phase II Status Ongoing studies but not recruiting Drug GSK4527226
ACP-204-006 ACP-204 in adults with Alzheimer's disease psychosis Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor ACADIA Pharmaceuticals Clinical Trial Phase III Status Currently recruiting Drug ACP-204
ADEPT-1 A study to assess efficacy and safety of KarXT for the treatment of psychosis associated with Alzheimer's disease dementia Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor Karuna Therapeutics Clinical Trial Phase III Status Currently recruiting Drug KarXT
ADEPT-3 Open-label extension study to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's disease Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor Karuna Therapeutics Clinical Trial Phase III Status Enrolling by invitation Drug KarXT (combines xanomeline with trospium)
ADEPT-4 A study to evaluate KarXT as a treatment for psychosis associated with Alzheimer's disease Dementia-related psychosis or Agitation in Alzheimer's dementia Sponsor Karuna Therapeutics Clinical Trial Phase III Status Currently recruiting Drug KarXT
Alzheimer Uniti Onlus language classes Italian classes for live-in carers of people with dementia to enable carers to communicate more effectively with the person with dementia and family and to be able to integrate into Italian society Target Audience Live-in Carers Communities BAME/BME Available languages Italian Initiative Type Training or Workshop
ASPIRE-FTD A study to evaluate the safety and effect of AVB-101, a gene therapy product, in subjects with a genetic sub-type of frontotemporal dementia Frontotemporal dementia Sponsor AviadoBio Ltd Clinical Trial Phase II Status Currently recruiting Drug AVB-101
CELIA A randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of BIIB080 in subjects with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Biogen Clinical Trial Phase II Status Ongoing studies but not recruiting Drug BIIB080
Clarity AD A study to confirm safety and efficacy of BAN2401 in participants with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Eisai Clinical Trial Phase III Status Ongoing studies but not recruiting Drug BAN2401
DIAN-TU Dominantly Inherited Alzheimer Network Trial: An opportunity to prevent dementia. A study of potential disease modifying treatments in individuals with a type of early onset Alzheimer's disease caused by a genetic mutation At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Washington University School of Medicine Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Lecanemab & E2814
DIAN-TU-001 A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer’s disease caused by a genetic mutation (DIAN-TU) At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Washington University School of Medicine Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Lecanemab & E2814
DNLI-H-0001 A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL593 in healthy participants and participants with Frontotemporal Dementia (FTD-GRN) Sponsor Denali Therapeutics Inc. Clinical Trial Phase II Status Ongoing studies but not recruiting Drug DNL593
DOPAD-3 A Phase 3 study of rotigotine in combination with rivastigmine in mild to moderate Alzheimer's disease Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor I.R.C.C.S. Fondazione Santa Lucia Clinical Trial Phase III Status Currently recruiting Drug Rotigotine
evoke evoke - A research study investigating Semaglutide in people with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Novo Nordisk A/S Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Semaglutide
GABRIELLA A clinical trial to look at how well RO7269162 works in people who are at risk of Alzheimer’s disease or who have mild cognitive impairment due to Alzheimer’s disease and how safe RO7269162 is at different doses At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Hoffmann-La Roche Clinical Trial Phase II Status Ongoing studies but not recruiting Drug RO7269162
MINDSET 1 A study to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's disease Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor Bristol-Myers Squibb Clinical Trial Phase III Status Currently recruiting Drug KarXT + KarX-EC
MINDSET 2 A study to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's disease Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor Bristol-Myers Squibb Clinical Trial Phase III Status Currently recruiting Drug KarXT + KarX-EC
MK-1167-008 A study to evaluate the efficacy and safety of MK-1167 in participants with Alzheimer's disease dementia Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor Merck Sharp & Dohme LLC Clinical Trial Phase II Status Ongoing studies but not recruiting Drug MK-1167
POLARIS-AD Phase 3, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of AR1001 in participants with early Alzheimer's disease Sponsor AriBio Co Clinical Trial Phase III Status Ongoing studies but not recruiting Drug AR1001
PRImus-AD Study to assess safety and efficacy of PRI-002 in patients with Mild Cognitive Impairment (MCI) to mild dementia due to Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor PRInnovation GmbH Clinical Trial Phase II Status Ongoing studies but not recruiting Drug PRI-002
TRAVELLER Master screening study to determine individuals with potential trial eligibility for Alzheimer's disease studies At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Hoffmann-La Roche Clinical Trial Phase III Status Currently recruiting
TRONTIER 1 A clinical trial of trontinemab in participants with early symptomatic Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor F. Hoffmann- La Roche Clinical Trial Phase III Status Currently recruiting Drug Trontinemab
